Sesen Bio's lead ADC shows treatment effect in late-stage bladder cancer study

Sesen Bio's lead ADC shows treatment effect in late-stage bladder cancer study  Seeking Alpha Sesen Bio (SESN) PT Raised to $3.50  Enterprise Leader Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three ...  StockhouseFull coverage

Read More ...
Sesen Bio's lead ADC shows treatment effect in late-stage bladder cancer study published May 22, 2018 at 02:32AM. Original Source Link : https://seekingalpha.com/news/3358339-sesen-bios-lead-adc-shows-treatment-effect-late-stage-bladder-cancer-study

loading...